# Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

> **NCT03257163** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 40 (estimated)

## Conditions studied

- Epstein-Barr Virus Positive
- Gastric Adenocarcinoma
- Mismatch Repair Protein Deficiency
- Stage IB Gastric Cancer AJCC v7
- Stage II Gastric Cancer AJCC v7
- Stage IIA Gastric Cancer AJCC v7
- Stage IIB Gastric Cancer AJCC v7
- Stage III Gastric Cancer AJCC v7
- Stage IIIA Gastric Cancer AJCC v7
- Stage IIIB Gastric Cancer AJCC v7
- Stage IIIC Gastric Cancer AJCC v7

## Interventions

- **DRUG:** Capecitabine
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03257163
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-29
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03257163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03257163, "Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03257163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*